Review and management of drug interactions with boceprevir and telaprevir - Wikidata - awgldk - TriplyDB

Review and management of drug interactions with boceprevir and telaprevir

Review and management of drug interactions with boceprevir and telaprevir

http://www.wikidata.org/entity/Q24628716

about

Current management and perspectives for HCV recurrence after liver transplantation Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation Drug-drug interactions during antiviral therapy for chronic hepatitis C Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes Treatment optimization for HIV/HCV co-infected patients.Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report Current and future therapies for hepatitis C virus infection.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Direct-acting antiviral agents for hepatitis C virus infection.Review article: prescribing medications in patients with cirrhosis - a practical guide.Management of viral hepatitis in liver transplant recipients What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Acute hepatitis C in an HIV-infected patient: a case report and review of literature Drug-drug interaction studies: regulatory guidance and an industry perspective CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.Boceprevir and personalized medicine in hepatitis C virus infection Optimal treatment with boceprevir for chronic HCV infection.Treatment decisions and contemporary versus pending treatments for hepatitis C.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?Safety of direct-acting antivirals in the treatment of chronic hepatitis C.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?New treatments for chronic hepatitis C: an overview for paediatricians.Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective.Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers.

P2860

Q22299427-E8C8F053-671D-4E79-96D9-EB1D087DB72D Q26864478-F5273734-A685-4DD8-8C12-E4A75D94D035 Q26864887-4E312F46-83A5-4780-AD2D-6E2DC54CB11F Q27022596-0A19AFA0-B04E-4DA0-8512-41045CE4B4BA Q28081216-0883305B-94C6-4300-A24A-D8D1B38A4992 Q30235034-C2500417-05C7-4ED7-8B22-46B6C16D7C9B Q33419369-49E0D0B8-EBBC-4BFA-850D-CF4A0E224FFC Q34036762-467C018D-844B-43FC-95C0-F8D092323CA8 Q34143327-558603D5-C640-4084-99E7-9FA3B89D7F62 Q34321440-CB01D034-4C2B-4F5C-BA02-1DA466925A20 Q34342554-65915BAF-2B3E-4121-874E-ADCD6FA738BF Q34779730-4CD7E183-BCFB-4DFF-9A37-EB986406D780 Q35019908-2E92AF63-3D47-4CB6-B285-99EFF61403EA Q35033091-B08421C3-ACC3-4B03-BDF4-8C9887B79FB0 Q35156383-85C33312-7F38-4D9E-BF83-5411D7EF1BEA Q35384561-B584453D-834E-46BD-8B2C-3693FBE7B897 Q35543019-36C3BEDC-D1C4-477D-B0BF-3C0FC51B0E49 Q36290804-6E271156-C6BB-468A-B83C-9AFA986A750B Q36668891-E9E59F1F-53E4-4993-8362-DEA8603BA9F5 Q36780300-D345F055-F501-4698-917F-617E5CBC8256 Q36951933-20D6076A-2698-44FD-A280-C527BCE202C9 Q37100669-6A027E63-82ED-42B5-A9AC-A3C28FD1BE4A Q37182990-23576C75-784C-48AC-B5BD-D6AD1AF51836 Q37418256-C6FDAE0E-A4BE-468E-80FE-2CDF1BE27E9F Q37525649-F33C98F7-7440-446F-A6FE-767328A32669 Q38066185-08365C82-7D0F-46C7-B488-61692F440CB1 Q38071383-15A3A104-AD93-4E8A-B8AC-F0860C587E2F Q38135774-9FB8E566-CA18-4B3B-9071-1698EEA5A228 Q38151586-2CB822D2-D4B9-400F-BDD7-CA9B3244411D Q38170504-E8B6A0F7-4971-4042-8C84-3DCA9A71D09A Q38189110-4D7906A1-D89D-423B-8785-D023ABE1CC15 Q38203823-89402FF0-DB22-4563-88F3-4E1CE4C16DE8 Q38210969-0B075AB5-08ED-4A3D-8935-49FEEC661475 Q38282842-319D9237-2F44-47A9-9E26-59476115DE42 Q38392453-E7711B0E-5C25-4F99-9261-0C0D10696757 Q38562886-E7A10BBC-075C-44EF-A385-7D22252B5858 Q38750141-74B4D313-156D-4BF2-94BE-55C6771F13C6 Q39007008-71C519B1-155F-4146-9F44-B7A082F8C04D Q39016874-707B84CA-D78B-4B43-886F-6609EDC60B63 Q39771933-192E88D5-AF38-40B7-9D41-E290E2115EC3

P2860

Review and management of drug interactions with boceprevir and telaprevir

http://www.wikidata.org/entity/Q24628716

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Review and management of drug interactions with boceprevir and telaprevir

@ast

Review and management of drug interactions with boceprevir and telaprevir

@en

Review and management of drug interactions with boceprevir and telaprevir

@nl

type

label

Review and management of drug interactions with boceprevir and telaprevir

@ast

Review and management of drug interactions with boceprevir and telaprevir

@en

Review and management of drug interactions with boceprevir and telaprevir

@nl

prefLabel

Review and management of drug interactions with boceprevir and telaprevir

@ast

Review and management of drug interactions with boceprevir and telaprevir

@en

Review and management of drug interactions with boceprevir and telaprevir

@nl

P1433

Q24628716-5B1C888B-8C67-42C2-9DB7-6C16E251F4A5

P1476

Q24628716-70ECEB0D-0864-4D6F-B176-45C611E424D1

P2093

Q24628716-35F2EEC8-E4C1-4710-A274-81D6DD5DF1F6

Q24628716-7F903C7C-9553-4AD3-89E3-56286BC99492

Q24628716-BA71C6FA-A393-4E4C-832C-5DEE2C4156F6

Q24628716-E422D45D-1D05-48A4-BD43-C5339A909811

P2860

Q24628716-158CC33C-E38D-43F6-8DD7-6C758D5B5DC4

Q24628716-27A7D733-7AD3-4729-A2C3-1E5467395AEE

Q24628716-2C1A43E0-D2B3-4049-80FE-255B20DE6436

Q24628716-2D889D22-C17B-4322-9A27-A4B1D1AD37D5

Q24628716-2ECF2B65-4E10-4D04-853D-5F4FD95574E3

Q24628716-38228ACF-F58C-4233-84E0-5D495F927EAF

Q24628716-38B2FCD7-237A-45F4-AAE0-ABD3EABCECE1

Q24628716-39BF39AC-0593-41DD-854F-DAF6FD8479C8

Q24628716-3EDEA761-BD7D-45B8-9C3A-AA0F0DF85A1F

Q24628716-4458B950-6DCD-46B7-981A-316CC3BE0BF1

P304

Q24628716-97AEA9F4-0DFA-4473-8CAC-F198749EB754

P31

Q24628716-F1A108F1-CCFE-4D81-97D2-FDCD3D6CFA44

P3181

Q24628716-429E5DA8-227E-4548-BA9A-54EC07A01258

P356

Q24628716-EB249872-B402-4B34-A18B-01465C1AF6DF

P407

Q24628716-9FE3A24C-362C-46DE-9E52-492106AAD002

P433

Q24628716-9788C254-EA7E-45B8-8557-2B14810325E0

P478

Q24628716-18BC3235-B8D9-4C2A-B461-92DAD400CB0A

P577

Q24628716-DA800868-077F-477B-98BF-4DE479718923

P5875

Q24628716-AC8CC4B3-ACF8-47F6-B7EA-1275D81A8655

P698

Q24628716-C86952BB-7720-443F-8EC1-867D51CF9C31

P932

Q24628716-5C57934B-0D81-46BD-9D12-C72D6571FED0

P3181

P356

P1433

P1476

Review and management of drug interactions with boceprevir and telaprevir

@en

P2093

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

James R Burton

http://www.w3.org/2001/XMLSchema#string

Jennifer J Kiser

http://www.w3.org/2001/XMLSchema#string

Peter L Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Progestin-only pills for contraception

Boceprevir for previously treated chronic HCV genotype 1 infection

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Boceprevir for untreated chronic HCV genotype 1 infection

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Implications of cytochrome P450 interactions when prescribing medication for hypertension.

Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

P304

1620-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4644161

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/HEP.25653

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221829890

http://www.w3.org/2001/XMLSchema#string

P698

22331658

http://www.w3.org/2001/XMLSchema#string

P932

3345276

http://www.w3.org/2001/XMLSchema#string